COVID-19-related stigma among infected people in Sweden; psychometric properties and levels of stigma in two cohorts as measured by a COVID-19 stigma scale.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 27 12 2022
accepted: 02 06 2023
medline: 23 6 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: epublish

Résumé

Epidemics have historically been accompanied by stigma and discrimination. Disease-related stigma has often been shown to have severe consequences for physical, mental and social wellbeing and lead to barriers to diagnosis, treatment and prevention. The aims of this study were to investigate if a HIV-related stigma measure could be adapted and valid and reliable to measure COVID-19-related stigma, and also to investigate levels of self-reported stigma and related factors among people in Sweden with experience of COVID-19 and compare levels of COVID-19-related stigma versus HIV-related stigma among persons living with HIV who had experienced a COVID-19 event. Cognitive interviews (n = 11) and cross-sectional surveys were made after the acute phase of the illness using a new 12-item COVID-19 Stigma Scale and the established 12-item HIV Stigma Scale in two cohorts (people who had experienced COVID-19 (n = 166/209, 79%) and people living with HIV who had experienced a COVID-19 event (n = 50/91, 55%). Psychometric analysis of the COVID-19 Stigma Scale was performed by calculating floor and ceiling effects, Cronbach's α and exploratory factor analysis. Levels of COVID-19 stigma between groups were analysed using the Mann-Whitney U test. Levels of COVID-19 and HIV stigma among people living with HIV with a COVID-19 event were compared using the Wilcoxon signed-rank test. The COVID-19 cohort consisted of 88 (53%) men and 78 (47%) women, mean age 51 (19-80); 143 (87%) living in a higher and 22 (13%) in a lower income area. The HIV + COVID-19 cohort consisted of 34 (68%) men and 16 (32%) women, mean age 51 (26-79); 20 (40%) living in a higher and 30 (60%) in a lower income area. The cognitive interviews showed that the stigma items were easy to understand. Factor analysis suggested a four-factor solution accounting for 77% of the total variance. There were no cross loadings, but two items loaded on factors differing from the original scale. All subscales had acceptable internal consistency, showed high floor and no ceiling effects. There was no statistically significant difference between COVID-19 stigma scores between the two cohorts or between genders. People living in lower income areas reported more negative self-image and concerns about public attitudes related to COVID-19 than people in higher income areas (median score 3 vs 3 and 4 vs 3 on a scale from 3-12, Z = -1.980, p = 0.048 and Z = -2.023, p = 0.024, respectively). People from the HIV + COVID-19 cohort reported more HIV than COVID-19 stigma. The adapted 12-item COVID-19 Stigma Scale may be valid and reliable for measurement of COVID-19-related stigma. However, specific items may need to be rephrased or replaced to better correspond to the COVID-19 context. People who had experienced COVID-19 reported low levels of COVID-19-related stigma in general but people from lower income areas had higher levels of negative self-image and concerns about public attitudes related to COVID-19 than people from areas with higher income, which may call for targeted interventions. Although exhibiting more pronounced HIV stigma levels, people living with HIV who had experienced COVID-19 reported COVID-19-related stigma of the same low magnitude as their peers not living with HIV.

Sections du résumé

BACKGROUND
Epidemics have historically been accompanied by stigma and discrimination. Disease-related stigma has often been shown to have severe consequences for physical, mental and social wellbeing and lead to barriers to diagnosis, treatment and prevention. The aims of this study were to investigate if a HIV-related stigma measure could be adapted and valid and reliable to measure COVID-19-related stigma, and also to investigate levels of self-reported stigma and related factors among people in Sweden with experience of COVID-19 and compare levels of COVID-19-related stigma versus HIV-related stigma among persons living with HIV who had experienced a COVID-19 event.
METHODS
Cognitive interviews (n = 11) and cross-sectional surveys were made after the acute phase of the illness using a new 12-item COVID-19 Stigma Scale and the established 12-item HIV Stigma Scale in two cohorts (people who had experienced COVID-19 (n = 166/209, 79%) and people living with HIV who had experienced a COVID-19 event (n = 50/91, 55%). Psychometric analysis of the COVID-19 Stigma Scale was performed by calculating floor and ceiling effects, Cronbach's α and exploratory factor analysis. Levels of COVID-19 stigma between groups were analysed using the Mann-Whitney U test. Levels of COVID-19 and HIV stigma among people living with HIV with a COVID-19 event were compared using the Wilcoxon signed-rank test.
RESULTS
The COVID-19 cohort consisted of 88 (53%) men and 78 (47%) women, mean age 51 (19-80); 143 (87%) living in a higher and 22 (13%) in a lower income area. The HIV + COVID-19 cohort consisted of 34 (68%) men and 16 (32%) women, mean age 51 (26-79); 20 (40%) living in a higher and 30 (60%) in a lower income area. The cognitive interviews showed that the stigma items were easy to understand. Factor analysis suggested a four-factor solution accounting for 77% of the total variance. There were no cross loadings, but two items loaded on factors differing from the original scale. All subscales had acceptable internal consistency, showed high floor and no ceiling effects. There was no statistically significant difference between COVID-19 stigma scores between the two cohorts or between genders. People living in lower income areas reported more negative self-image and concerns about public attitudes related to COVID-19 than people in higher income areas (median score 3 vs 3 and 4 vs 3 on a scale from 3-12, Z = -1.980, p = 0.048 and Z = -2.023, p = 0.024, respectively). People from the HIV + COVID-19 cohort reported more HIV than COVID-19 stigma.
CONCLUSIONS
The adapted 12-item COVID-19 Stigma Scale may be valid and reliable for measurement of COVID-19-related stigma. However, specific items may need to be rephrased or replaced to better correspond to the COVID-19 context. People who had experienced COVID-19 reported low levels of COVID-19-related stigma in general but people from lower income areas had higher levels of negative self-image and concerns about public attitudes related to COVID-19 than people from areas with higher income, which may call for targeted interventions. Although exhibiting more pronounced HIV stigma levels, people living with HIV who had experienced COVID-19 reported COVID-19-related stigma of the same low magnitude as their peers not living with HIV.

Identifiants

pubmed: 37343027
doi: 10.1371/journal.pone.0287341
pii: PONE-D-22-35422
pmc: PMC10284413
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0287341

Informations de copyright

Copyright: © 2023 Reinius et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

AIDS. 2021 Jan 1;35(1):115-123
pubmed: 33048876
J Behav Med. 2020 Jun;43(3):341-345
pubmed: 32333185
Lancet HIV. 2020 Feb;7(2):e129-e140
pubmed: 31776098
J Affect Disord. 2021 Jan 1;278:15-22
pubmed: 32949869
BMJ Open. 2016 Jul 13;6(7):e011453
pubmed: 27412106
J Multidiscip Healthc. 2022 Feb 09;15:247-258
pubmed: 35173439
Indian J Tuberc. 2020 Jul;67(3):284-285
pubmed: 32825854
AIDS Behav. 2018 Dec;22(12):3795-3806
pubmed: 29417350
Pak J Med Sci. 2020 Nov-Dec;36(7):1471-1477
pubmed: 33235559
Int J Environ Res Public Health. 2020 Aug 31;17(17):
pubmed: 32878180
Front Public Health. 2022 Oct 14;10:992046
pubmed: 36311615
PLoS One. 2023 Apr 20;18(4):e0284582
pubmed: 37079579
Int J Environ Res Public Health. 2021 Dec 11;18(24):
pubmed: 34948690
J Adv Nurs. 2003 Apr;42(1):57-63
pubmed: 12641812
Health Sci Rep. 2022 Feb 18;5(2):e520
pubmed: 35224221
Nature. 2020 Apr;580(7805):574
pubmed: 32317784
Int J Environ Res Public Health. 2020 Dec 10;17(24):
pubmed: 33321881
Am J Phys Med Rehabil. 2023 May 1;102(5):433-443
pubmed: 36753451
BMJ Open. 2020 Dec 30;10(12):e046620
pubmed: 33380488
PLoS One. 2021 Apr 14;16(4):e0247962
pubmed: 33852581
Psychiatry Clin Neurosci. 2020 Oct;74(10):566-568
pubmed: 32779787
Health Qual Life Outcomes. 2017 May 30;15(1):115
pubmed: 28558805
PLoS One. 2020 Dec 18;15(12):e0244172
pubmed: 33338064
AIDS Behav. 2021 Jan;25(1):1-8
pubmed: 32918640
Curr HIV/AIDS Rep. 2022 Feb;19(1):54-75
pubmed: 34826067
Int J Environ Res Public Health. 2021 May 19;18(10):
pubmed: 34069754
PLoS One. 2021 Jul 1;16(7):e0253371
pubmed: 34197498
Int J Health Plann Manage. 2021 Jan;36(1):215-218
pubmed: 32845533
Res Nurs Health. 2001 Dec;24(6):518-29
pubmed: 11746080
Front Public Health. 2020 Aug 28;8:429
pubmed: 32984238
J Int AIDS Soc. 2013 Nov 13;16(3 Suppl 2):18640
pubmed: 24242258

Auteurs

Maria Reinius (M)

Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.

Veronica Svedhem (V)

Medical Unit Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden.
Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.

Judith Bruchfeld (J)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Heidi Holmström Larm (H)

Medical Unit Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden.

Malin Nygren-Bonnier (M)

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Medical Unit Occupational Therapy and Physiotherapy, Women's Health and Allied Health Professionals Theme, Karolinska University Hospital, Huddinge, Sweden.

Lars E Eriksson (LE)

Medical Unit Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden.
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
School of Health and Psychological Sciences, City, University of London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH